No headlines found.
No press releases found.
No news found.
The Defiance Daily Target 2X Long MRNA ETF (MRNX) provides investors with amplified long exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company focused on the development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Because the Fund seeks daily leveraged investment results, it is very different from most other exchange-traded funds. It is also riskier than alternatives that do not use leverage. The Fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The Fund does not seek to achieve its stated investment objective for a period other than a single trading day. The Fund is an actively managed exchange traded fund ("ETF") that attempts to achieve two times (200%) the daily percentage change in the share price of the Underlying Security by employing derivatives, namely swap agreements and/or listed options contracts.
Defiance Daily Target 2X Long Mrna ETF trades on the ARCA stock market under the symbol MRNX.
As of July 13, 2026, MRNX stock price declined to $37.55 with 28,104 million shares trading.
MRNX has a beta of 2.16, meaning it tends to be more sensitive to market movements. MRNX has a correlation of 0.05 to the broad based SPY ETF.
MRNX has a market cap of $3.76 million. This is considered a Sub-Micro Cap stock.
MRNX support price is $34.29 and resistance is $43.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNX shares will trade within this expected range on the day.
